PTC THERAPEUTICS, INC.

Form 4 June 19, 2015

## FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB APPROVAL OMB** 

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(City)

Common

Stock

(Print or Type Responses)

1. Name and Address of Reporting Person \* Jacobson Allan Steven

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

PTC THERAPEUTICS, INC.

[PTCT]

06/18/2015

(Check all applicable)

(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)

X\_ Director Officer (give title below)

10% Owner Other (specify

C/O PTC THERAPEUTICS. INC., 100 CORPORATE COURT

> (Street) 4. If Amendment, Date Original

> > (Zip)

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

SOUTH PLAINFIELD, NJ 07080

(State)

06/18/2015

1. Title of 2. Transaction Date 2A. Deemed 3. Security (Month/Day/Year) Execution Date, if (Instr. 3) (Month/Day/Year)

4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 5. Amount of Securities Beneficially Owned Following Reported

> Transaction(s) (Instr. 3 and 4)

6. Ownership 7. Nature of Form: Direct Indirect (D) or Beneficial Ownership Indirect (I) (Instr. 4) (Instr. 4)

Price Code V Amount (D)

\$  $S^{(1)}$ 

5,000 D 50.13

(2)

(A)

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

6,848

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

#### Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. ctionNumber of Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Pri Deriv Secui (Instr
				Code V	(A) (I	D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 51						01/02/2016	01/01/2025	Common Stock	12,000	
Stock Option (right to buy)	\$ 27.05						01/28/2015	01/27/2024	Common Stock	10,000	
Stock Option (right to buy)	\$ 10.85						(3)	05/15/2023	Common Stock	63,000	
Stock Option (right to buy)	\$ 218.4						<u>(4)</u>	01/10/2022	Common Stock	83	
Stock Option (right to buy)	\$ 490.8						<u>(4)</u>	04/27/2021	Common Stock	250	
Stock Option (right to buy)	\$ 1,149.6						<u>(4)</u>	02/02/2020	Common Stock	83	
Stock Option (right to buy)	\$ 508.8						<u>(4)</u>	10/07/2019	Common Stock	83	
Stock Option (right to buy)	\$ 626.4						<u>(4)</u>	04/18/2007	Common Stock	83	

#### **Reporting Owners**

Reporting Owner Name / Address

Director 10% Owner Officer Other

Jacobson Allan Steven
C/O PTC THERAPEUTICS, INC.
100 CORPORATE COURT
SOUTH PLAINFIELD, NJ 07080

## **Signatures**

/s/ Colleen Diver Johnson, Attorney-in-Fact

06/19/2015

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan for the primary purposes of covering tax obligations associated with a restricted stock vesting event and diversification.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$49.89 (2) to \$50.36 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This option was granted on May 15, 2013 and vests over three years, with 8.33% of the shares underlying the option vested on August 15, (3) 2013 and an additional 8.33% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter.
- (4) Currently exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3